San Diego‑based Iambic described a physics‑informed AI and automation platform that has accelerated small‑molecule discovery timelines to roughly two years from chemistry to clinic. The company’s approach couples automated synthetic platforms with algorithmic design and attracted early partners; Iambic says the system has already delivered clinic‑ready candidates. The profile highlights a broader industry push to combine machine learning, physics constraints and robotics to shorten discovery timelines and de‑risk early development, though independent validation and reproducibility of rapid cycles remain key scrutiny points.